# A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

> **NCT05496738** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 59 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-07264660 intravenous single ascending dose
- **DRUG:** PF-07264660 subcutaneous multiple ascending dose
- **OTHER:** Intravenous placebo
- **OTHER:** subcutaneous placebo

## Key facts

- **NCT ID:** NCT05496738
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-16
- **Primary completion:** 2024-05-06
- **Final completion:** 2024-05-06
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496738, "A Preliminary Study to Evaluate PF-07264660 in Healthy Participants". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05496738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*